Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Intec Pharma Ltd.NTEC · Entity 146542 | Director | July 15, 2020 | July 17, 2020 |
| LIGAND PHARMACEUTICALS INCLGND · Entity 3825 | Director | June 05, 2026 | June 09, 2026 |
| Travere Therapeutics, Inc.RTRX · Entity 1562 | Director | May 08, 2019 | May 11, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Intec Pharma Ltd.
Report date July 15, 2020 · Filed July 17, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.31 · Expires 2027-07-15 | Direct | 40,000 |
Reported balance
After 2020-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-15 · Grant · Acquired 40,000 · Balance 40,000 F1: The stock option vests and becomes exercisable as to one-third of the total shares on July 15, 2021 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through July 15, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable as to one-third of the total shares on July 15, 2021 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through July 15, 2023.
LIGAND PHARMACEUTICALS INC
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,622 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 836 · Balance 42,622 F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $237.00 · Expires 2036-06-05 | Direct | 2,938 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Grant · Acquired 2,938 · Balance 2,938 F2: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
F2: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
Travere Therapeutics, Inc.
Report date May 08, 2019 · Filed May 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,000 |
Reported balance
After 2019-05-08 transaction · row 1
1 source rowRow 1 · 2019-05-08 · Grant · Acquired 2,000 · Balance 29,000 |
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.94 · Expires 2029-05-07 | Direct | 8,000 |
Reported balance
After 2019-05-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-05-08 · Grant · Acquired 8,000 · Balance 8,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2025 Filed Sep 4, 2025 21:47 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 115 | $162.52 | $18,689.66 |
DisclosureSEC source: 0002001011-25-000068 · edgardoc.xml · nonDerivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,607 F1 · shares: The transaction reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $162.3600 to $162.6000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 21:47 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 267 | $161.51 | $43,124.10 |
DisclosureSEC source: 0002001011-25-000068 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,722 F1 · shares: The transaction reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $161.0300 to $162.0200. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 21:03 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 467 | $131.88 | $61,585.86 |
DisclosureSEC source: 0002001011-25-000059 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,989 F1 · shares: The transaction reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. Read SEC document |
| July 10, 2025 Filed Jul 11, 2025 22:17 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 934 | $125.00 | $116,750.00 |
DisclosureSEC source: 0002001011-25-000053 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,456 F1 · shares: The transaction reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 23:21 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,783 | $0.00 Strike: $105.99 | $0.00 |
DisclosureSEC source: 0002001011-25-000041 · edgardoc.xml · derivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,783 Underlying: Common Stock · 5,783 shares Expires 2035-06-06 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 23:21 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 1,209 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-25-000041 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,390 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| January 17, 2025 Filed Jun 3, 2025 00:05 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,406 | $0.00 Strike: $52.30 | $0.00 |
DisclosureSEC source: 0002001011-25-000036 · edgardoc.xml · derivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,406 shares Expires 2025-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This Option was previously reported as a Grant of 2,754 shares, which vested in full on April 24, 2016, at an exercise price of $89.7500 per share. Read SEC document |
| January 17, 2025 Filed Jun 3, 2025 00:05 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 2,406 | $52.30 | $125,833.80 |
DisclosureSEC source: 0002001011-25-000036 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2024 Filed Jun 19, 2024 01:26 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,444 | $0.00 Strike: $80.06 | $0.00 |
DisclosureSEC source: 0002001011-24-000058 · edgardoc.xml · derivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,444 Underlying: Common Stock · 5,444 shares Expires 2034-06-14 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 14, 2024. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 14, 2024 Filed Jun 19, 2024 01:26 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 1,252 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-24-000058 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,775 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 14, 2024. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| April 24, 2024 Filed Apr 26, 2024 22:35 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,893 | $0.00 Strike: $39.35 | $0.00 |
DisclosureSEC source: 0002001011-24-000048 · edgardoc.xml · derivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,893 shares Expires 2024-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This Option was previously reported as a Grant of 3,312 shares, which vested in full on April 24, 2015, at an exercise price of $67.53 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. Read SEC document |
| April 24, 2024 Filed Apr 26, 2024 22:35 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 2,893 | $39.35 | $113,839.55 |
DisclosureSEC source: 0002001011-24-000048 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 22:54 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,461 | $0.00 Strike: $73.76 | $0.00 |
DisclosureSEC source: 0000886163-23-000041 · edgardoc.xml · derivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,461 Underlying: Common Stock · 5,461 shares Expires 2033-06-09 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 9, 2023. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 22:54 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 1,142 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-23-000041 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,630 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 9, 2023. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| May 16, 2023 Filed May 18, 2023 21:18 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 4,444 | $77.20 | $343,080.80 |
DisclosureSEC source: 0000899243-23-013275 · doc4.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,488 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $77.20 to $77.24. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: The number reflected in Column 5 reconciles the total number of shares beneficially held following the transactions reported herein. Read SEC document |
| May 08, 2023 Filed May 10, 2023 23:15 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,408 | $0.00 Strike: $18.82 | $0.00 |
DisclosureSEC source: 0000899243-23-012541 · doc4.xml · derivative · entry 4 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,408 shares Expires 2023-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 11, 2013, and will fully vest on the first anniversary of the grant date. Read SEC document |
| May 08, 2023 Filed May 10, 2023 23:15 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 589 | $77.10 | $45,410.37 |
DisclosureSEC source: 0000899243-23-012541 · doc4.xml · nonDerivative · entry 3 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,213 F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $77.02 to $77.19. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 08, 2023 Filed May 10, 2023 23:15 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 5,819 | $76.51 | $445,217.51 |
DisclosureSEC source: 0000899243-23-012541 · doc4.xml · nonDerivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,802 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $76.00 to $76.965. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 08, 2023 Filed May 10, 2023 23:15 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 6,408 | $18.82 | $120,598.56 |
DisclosureSEC source: 0000899243-23-012541 · doc4.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 23:31 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 6,623 | $0.00 Strike: $67.03 | $0.00 |
DisclosureSEC source: 0000899243-22-039410 · doc4.xml · derivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,623 Underlying: Common Stock · 6,623 shares Expires 2032-12-22 F1 · derivative.exercise_date: Grant to reporting person of stock options that will vest and become exercisable on December 22, 2023. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 22:45 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,340 | $0.00 Strike: $79.29 | $0.00 |
DisclosureSEC source: 0000886163-22-000080 · edgardoc.xml · derivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,340 Underlying: Common Stock · 4,340 shares Expires 2032-06-10 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2022. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 22:45 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 1,004 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-22-000080 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,213 F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2022. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 21:34 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,335 | $0.00 Strike: $12.53 | $0.00 |
DisclosureSEC source: 0000886163-22-000033 · edgardoc.xml · derivative · entry 3 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,335 shares Expires 2022-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on May 31, 2012, and fully vested on the first anniversary of the grant date. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 21:34 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 908 | $102.62 | $93,178.96 |
DisclosureSEC source: 0000886163-22-000033 · edgardoc.xml · nonDerivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,209 Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 21:34 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 7,335 | $12.53 | $91,907.55 |
DisclosureSEC source: 0000886163-22-000033 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 01:24 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,269 | $0.00 Strike: $115.39 | $0.00 |
DisclosureSEC source: 0000886163-21-000090 · edgardoc.xml · derivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,269 Underlying: Common Stock · 3,269 shares Expires 2031-06-04 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 04, 2021. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 01:24 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 630 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-21-000090 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,782 F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 04, 2021. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| May 11, 2021 Filed May 14, 2021 00:57 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,835 | $0.00 Strike: $10.12 | $0.00 |
DisclosureSEC source: 0000886163-21-000071 · edgardoc.xml · derivative · entry 3 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,835 shares Expires 2012-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 01, 2011, and fully vested on the first anniversary of the grant date. Read SEC document |
| May 11, 2021 Filed May 14, 2021 00:57 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 391 | $128.56 | $50,266.96 |
DisclosureSEC source: 0000886163-21-000071 · edgardoc.xml · nonDerivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,152 F1 · shares: Represents shares withheld by the Issuer in payment of the exercise price of options. Read SEC document |
| May 11, 2021 Filed May 14, 2021 00:57 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 4,835 | $10.12 | $48,930.20 |
DisclosureSEC source: 0000886163-21-000071 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,543 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:18 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $10.12 | $0.00 |
DisclosureSEC source: 0000886163-21-000045 · edgardoc.xml · derivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,835 Underlying: Common Stock · 2,500 shares Expires 2012-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 01, 2011, and fully vested on the first anniversary of the grant date. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:18 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 2,500 | $10.12 | $25,300.00 |
DisclosureSEC source: 0000886163-21-000045 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:30 UTC | Intec Pharma Ltd. NTEC · Entity 146542 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001213900-20-017808 · ownership.xml · derivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Ordinary Shares · 40,000 shares Expires 2027-07-15 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to one-third of the total shares on July 15, 2021 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through July 15, 2023. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 22:33 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,468 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0000886163-20-000076 · edgardoc.xml · derivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,468 Underlying: Common Stock · 2,468 shares Expires 2030-06-10 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2020. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 22:33 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 831 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-20-000076 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,208 F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2020. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| August 23, 2019 Filed Aug 27, 2019 20:20 UTC | Intec Pharma Ltd. NTEC · Entity 146542 | PurchaseOrdinary Shares | 100,000 | $0.46 | $45,900.00 |
DisclosureSEC source: 0001213900-19-016793 · ownership.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,761 Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 22:48 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,071 | $0.00 Strike: $113.59 | $0.00 |
DisclosureSEC source: 0000886163-19-000105 · edgardoc.xml · derivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,071 Underlying: Common Stock · 4,071 shares Expires 2029-06-06 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 06, 2019. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 22:48 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 835 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-19-000105 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,377 F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 06, 2019. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| May 14, 2019 Filed May 14, 2019 23:56 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $17.88 | $0.00 |
DisclosureSEC source: 0000886163-19-000080 · edgardoc.xml · derivative · entry 3 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2019-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option becomes exercisable in twelve successive equal monthly installments upon completion of each calendar month of service beginning 5/29/09. Read SEC document |
| May 14, 2019 Filed May 14, 2019 23:56 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 2,500 | $112.92 | $282,300.00 |
DisclosureSEC source: 0000886163-19-000080 · edgardoc.xml · nonDerivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,542 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.24 to $113.23, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 14, 2019 Filed May 14, 2019 23:56 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 2,500 | $17.88 | $44,700.00 |
DisclosureSEC source: 0000886163-19-000080 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:35 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantEmployee stock option (right to buy) · Derivative | 8,000 | $0.00 Strike: $17.94 | $0.00 |
DisclosureSEC source: 0001209191-19-029154 · doc4.xml · derivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2029-05-07 Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:35 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029154 · doc4.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,000 Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 22:24 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 2,500 | $275.04 | $687,610.00 |
DisclosureSEC source: 0000886163-18-000141 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,142 F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 05, 2017, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.12 to $277.03, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 22:50 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 2,500 | $207.48 | $518,699.25 |
DisclosureSEC source: 0000886163-18-000102 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,642 F1 · shares: The transaction reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 05, 2017, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $205.06 to $208.68, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 20:41 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,474 | $0.00 Strike: $76.77 | $0.00 |
DisclosureSEC source: 0000899243-18-017599 · doc4.xml · derivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,474 Underlying: Common Stock · 2,474 shares Expires 2028-06-18 F1 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 19, 2018. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 20:41 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 493 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017599 · doc4.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,142 F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 19, 2018. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 19, 2018 Filed Jul 3, 2018 22:42 UTC Amendment | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,474 | $0.00 Strike: $195.91 | $0.00 |
DisclosureSEC source: 0000886163-18-000097 · edgardoc.xml · derivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,474 Underlying: Common Stock · 2,474 shares Expires 2028-06-18 F1 · derivative.exercise_price: This amendment is being filed to correct the exercise price listed in item 2 of Table II in order to reflect the market closing price on the grant date. F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 19, 2018. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| May 14, 2018 Filed Feb 7, 2019 23:19 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GiftCommon Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-19-000029 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,049 Read SEC document |
| May 09, 2018 Filed May 12, 2018 01:09 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $26.52 | $0.00 |
DisclosureSEC source: 0001209191-18-029722 · doc4.xml · derivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-05-08 F1 · derivative.exercise_date: The option shall vest in 4 equal quarterly installments following the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.